preCARDIA
preCARDIA developed an inpatient partially implantable device for treating patients with Acute Decompensated Heart Failure (ADHF). It is based on the invention of Dr. Navin Kapur, Interventional Cardiologist and Advanced Heart Failure/Cardiac Transplant specialist, and Director of the Acute Circulatory Support Program at Tufts Medical Center and Dr. Richard Karas, M.D., Ph.D former CSO and former Executive Director Molecular Cardiology Research Institute (MCRI) Tufts Medical Center. The company was acquired by Abiomed in 2021.
Sector
Medical Devices
Strategy
MD Start
Status
Exit
Website
Abiomed Acquires preCARDIA
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.